News

Currently, the company is carrying out a Phase II trial to show the clinical efficacy of Oxabact, in Primary Hyperoxaluria (PH), a rare autosomal recessive disorder leading to

Suglat Tablets are discovered through a research collaboration and is being jointly developed by Astellas and Kotobuki Pharmaceutical (Kotobuki). The company said that SGLTs are membrane proteins that

Iconic’s lead clinical-stage program is a novel recombinant human chimeric protein therapeutic, hI-con1, licensed from Yale University. hI-con1 binds tissue factor, a promoter of inflammation and angiogenesis, key

Apricus CEO Richard Pascoe noted that the company is excited to have completed the first of several product shipments of Vitaros to different territories in Europe in 2014.

Under the agreement, Astellas will pay $7.3m to the settling parties. The Department of Justice had investigated Astellas for alleged off-label promotion of MYCAMINE for pediatric use, a

This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft

The actions taken are consistent with AMRI’s ongoing efforts to consolidate its facility resources to more effectively utilize its discovery and development resource pool and to further reduce

DCR-MYC is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. The company

The drug being developed is a low cost cure for drug-resistant malaria that is as safe as chloroquine, a frontline drug used for many years until rendered ineffective